MedTrace Logo

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

NCT04526574 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1796

Last updated 2022-07-08

Study results available
· View outcomes & findings →

Summary

Study of the safety and immunogenicity of 20vPnC and influenza vaccine administered at the same visit or separately

Conditions

  • Pneumococcal Disease

Interventions

BIOLOGICAL

Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)

Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)

OTHER

Saline

Normal saline for injection

BIOLOGICAL

Influenza vaccine

Seasonal inactivated influenza vaccine (SIIV)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2021-06-29
Completion
2021-06-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04526574 on ClinicalTrials.gov